Furthermore, to test the ability of miR-340 to specifically target NRAS mRNA, we verified that both sequences binding this miRNA were not conserved in KRAS or HRAS 3′UTRs (data not shown); coherently, miR-340 overexpression did not decrease KRAS or HRAS mRNA levels in GBM cells (Supplementary Figure 2A–2B). The gene discussed is HRAS; the disease is glioblastoma.